Dr. Carson Discusses Mogamulizumab as Potential Treatment for CTCL

Kenneth R. Carson, MD
Published: Wednesday, Jun 18, 2014

Kenneth R. Carson, MD, assistant professor, Division of Oncology, Washington University, discusses mogamulizumab as a potential treatment for patients with relapsed or refractory cutaneous T cell lymphoma (CTCL).

Carson says mogamulizumab is a new anti-CCR4 monoclonal antibody. CCR4 is expressed on most cutaneous lymphoma T cells. This antibody, Carson says, is glycoengineered to enhance antibody-dependent cellular cytotoxicity.

Preliminary results from phase II studies have suggested that single-agent mogamulizumab enhances disease response in patients who have relapsed or refractory CTCL. The antibody is also well tolerated, Carson says.

Kenneth R. Carson, MD, assistant professor, Division of Oncology, Washington University, discusses mogamulizumab as a potential treatment for patients with relapsed or refractory cutaneous T cell lymphoma (CTCL).

Carson says mogamulizumab is a new anti-CCR4 monoclonal antibody. CCR4 is expressed on most cutaneous lymphoma T cells. This antibody, Carson says, is glycoengineered to enhance antibody-dependent cellular cytotoxicity.

Preliminary results from phase II studies have suggested that single-agent mogamulizumab enhances disease response in patients who have relapsed or refractory CTCL. The antibody is also well tolerated, Carson says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x